AMPIO PHARMACEUTICALS, INC. AMPE Income Statement

Ampio pharmaceuticals, inc. (AMPE)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Product and service revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67	58	50	50	50	50	50	50	43	0	0	-	0	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses
Research and development
-	-	-	-	-	-	-	-	-	10,097	8,264	8,024	7,731	10,402	13,185	15,050	15,358	14,967	13,441	15,976	18,466	22,376	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
15,312	12,622	8,614	6,370	6,348	6,829	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	-	6,648	3,641	2,655	0	0	0
Research and development - related party (Note 9)
-	-	-	-	-	-	-	-	-	323	359	395	143	143	143	143	143	143	54	84	115	113	0	0	0	-	-	-	-	-	-	-	-	-	0	0	0	0	0
General and administrative
6,609	5,954	5,353	4,364	3,936	4,355	4,742	5,099	5,423	5,255	5,123	5,565	5,787	6,536	8,099	8,190	9,293	9,055	0	0	0	-	-	0	0	-	7,465	6,607	5,602	5,826	3,902	4,596	4,436	4,504	5,336	4,669	0	0	0
Selling, general and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
21,921	18,576	13,967	10,735	10,285	11,184	13,523	14,689	16,248	15,676	13,747	13,985	13,662	17,082	21,428	23,384	24,796	24,167	0	0	0	-	-	-	30,463	24,073	20,293	17,151	12,960	11,870	12,663	12,626	11,924	11,152	9,022	7,390	0	0	0
Loss from operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense)
Interest income (expense)
64	77	51	40	19	-5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest (expense) income
-	-	-	-	-	-	-	-	-	3	6	9	16	23	18	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest (expense) income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	18	22	0	0	0
Unrealized loss on fair value of debt instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,585	0	0	0	-	-
Derivative gain
8,860	4,869	2,953	12,753	16,523	45,298	2,799	-6,092	-11,731	-36,218	1,893	2,324	211	-915	-715	0	0	-	0	-	-	-	-	-	-	-516	-444	16	-77	205	494	560	-450	-1,555	0	0	0	-	-
Unrealized loss on trading security
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on trading security
-	-	-	-	-	-	-	-	-	-	-	-	-176	-146	64	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	15	22	22	21	17	11	10	6	4	2	0	0	0
Loss from equity investment in Aytu BioScience, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,043	-1,043	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income (expense)
8,924	4,946	2,882	12,670	16,419	45,170	0	0	0	-	1,627	2,125	-640	-2,081	-1,670	-1,023	-326	59	182	188	183	142	20	-235	-378	-504	-428	38	-55	227	512	572	-439	-7,142	-7,517	-7,797	0	0	0
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-24,107	0	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,606	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-33,713	-33,035	-34,949	-36,168	-39,048	-36,756	-33,336	-30,821	-24,528	-19,252	-15,676	0	-	0	0	-	-	-	-	-	-	-
Net loss applicable to non-controlling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,703	-1,328	-1,118	-1,001	-923	-875	-785	-719	-519	0	0	0	-	-	-	-	-	-	-	-	-	-
Net loss, before income tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-12,101	-12,010	-12,333	-18,276	-16,534	0	0	0	-
Foreign tax expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net (loss) income
-12,997	-13,630	-11,085	1,935	6,134	33,986	-10,665	-20,719	-27,948	-51,891	-12,120	-11,859	-14,303	-19,163	-26,023	-29,188	-31,491	-32,010	-31,707	-33,830	-35,166	-38,125	-35,226	-32,140	-30,042	-24,008	-20,672	-17,062	-12,965	-11,593	-12,101	-12,093	-12,415	-18,359	-16,616	-15,187	0	0	0
Net (loss) income per common share: Basic
-0.03	0.00	-0.05	0.00	-0.05	-	0.06	0.05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (loss) income per common share: Diluted
-0.04	-0.01	-0.05	-0.03	-0.05	-	-0.02	-0.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic weighted-average common share outstanding
159,054	154,062	142,207	115,031	111,104	-	96,930	86,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average number of common shares outstanding: Diluted
160,558	152,458	142,207	118,770	111,104	-	115,346	92,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
From continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.14	-0.10	-0.11	-0.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
From discontinuing operations and non-controlling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	-0.04	-0.03	-0.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic and diluted net (loss) income per common share
-	-	-	-	-	-	-	-	0.27	-0.66	-0.06	-0.04	-0.03	-0.06	-0.07	-0.10	-0.13	-0.20	-0.14	-0.14	-0.14	-0.18	-0.18	-0.17	-0.23	-0.19	-0.16	-0.17	-0.11	-0.10	-0.07	-0.08	-0.09	-0.03	-0.09	-0.10	-0.49	-0.14	-0.07
Weighted average number of common shares outstanding
-	-	-	-	-	-	-	-	82,943	75,093	68,232	60,623	57,240	57,217	53,842	52,016	52,016	51,998	51,998	51,989	51,981	52,068	51,969	51,917	44,950	41,907	37,106	37,090	37,072	37,069	36,477	31,260	31,126	29,065	28,679	28,284	18,025	17,107	17,069